TIGP (BIO)—Single Cell "Not Just" Profilings

Abstract

In the era of systemic therapy, mapping the immune microenvironment has become a primary determinant in understanding disease progression and therapeutic response. However, the true value of high-dimensional single-cell analysis lies not in the mere descriptive cataloging of cell types, but in bridging the gap between multi-omic profiling and the discovery of actionable biological mechanisms. By integrating transcriptomic, epigenomic, proteomic, and metabolic data at single-cell resolution, we move beyond "cell-type counting" to capture how individual cells interpret environmental cues, chronic stress signals, and regulatory rewiring. 
This seminar explores the transition from high-dimensional observations to the mechanistic understanding of immune dysfunction. Using diverse cancer and immunocompromised states as models, I will demonstrate how multi-omic landscapes reveal the orchestration of multi-lineage exhaustion affecting both natural killer cells and T cells. Moving from mechanistic validation toward manipulation, we leverage our understanding of the tumor-derived ligand landscape and localized niches to design in situ cancer vaccines. By building upon these validated anti-tumor immune circuits, we aim to move forward with therapeutic designs that can effectively reverse immune exclusion.
Looking forward, we are advancing these insights into real-world applications. We are actively working to move our in situ cancer vaccine designs toward clinical purposes to address therapeutic resistance. In parallel, we utilize population-level single-cell analysis as an exploratory tool to gain detailed observations across large cohorts, providing a systems-level framework for developing more predictive biomarkers and durable, patient-tailored therapies.

► 線上視訊請點選【連結】加入。

附件下載